(Q36306264)

13 August 2017

1 reference

title

Angiogenic inhibitors: a new therapeutic strategy in oncology (English)

1 reference

13 August 2017

4

Napoleone Ferrara

1 reference

13 August 2017

Giampietro Gasparini

1

1 reference

13 August 2017

Raffaele Longo

series ordinal

2

1 reference

13 August 2017

Masakazu Toi

series ordinal

3

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

11

1 reference

13 August 2017

page(s)

562-577

1 reference

Tumorigenesis and the angiogenic switch

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Self-regulation of growth in three dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Mechanisms and future directions for angiogenesis-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Endogenous inhibitors of angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Heterogeneous vascular dependence of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

A surrogate marker to monitor angiogenesis at last

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Influence of unrecognized molecular heterogeneity on randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Clinical trial design for target-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Integrins and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Looking for a good endothelial address

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Update on clinical trials targeting vascular endothelial growth factor in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Targeted therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0342

7 January 2021

Identifiers

DOI

10.1038/NCPONC0342

1 reference

Dimensions Publication ID

13 August 2017

1024004766

0 references

1 reference